|Bid||1.4300 x 1800|
|Ask||1.4300 x 900|
|Day's range||1.4100 - 1.6500|
|52-week range||0.6800 - 7.8700|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||N/A|
|Earnings date||15 May 2023 - 19 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.33|
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on March 23, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 95,000 restricted stock unit awards (RSUs) to f
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?